Ophthalmology could become the next space for Samsung Bioepis’ biosimilar drive to thrive in, after the presentation of new data on a copy of Lucentis (ranibizumab).
The South Korean company has announced that the primary endpoints have been met in the Phase III trial comparing the efficacy, safety and immunogenicity of SB11, its biosimilar candidate, to the reference product in patients with neovascular age-related macular degeneration (nAMD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze